We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -38.00 | -0.32% | 11,988.00 | 12,014.00 | 12,018.00 | 12,144.00 | 11,882.00 | 12,070.00 | 2,340,814 | 16:35:09 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.28 | 186.27B |
From Apr 2019 to Apr 2024
LONDON--AstraZeneca PLC (AZN.LN) Friday said a key committee of the European Medicines Agency had issued an opinion recommending approval of "saxa/dapa" tablets for treating adults with Type-2 diabetes.
The bio-pharmaceutical company said the positive opinion from the Committee for Medicinal Products for Human Use would now be reviewed by the European Commission, which holds the power to approve medicines for the European Union.
Saxa/dapa is a fixed-dose combination of saxagliptin and dapagliflozin, the company said.
Shares at 1145 GMT were down 43.50 pence, or 1.1%, at 3968 pence, valuing the company at 50.17 billion pounds ($73.72 billion).
Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga
(END) Dow Jones Newswires
May 27, 2016 08:27 ET (12:27 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
